Siemens Healthineers Begins Diagnostics Business Separation, Introduces Olyrian Diagnostics as New Standalone Brand
Siemens Healthineers has announced the initiation of the carve-out process for its in vitro diagnostics business, marking a significant development in the company’s organizational strategy and the future direction of its diagnostics operations. The business will operate under a new name, Olyrian Diagnostics, as it prepares to become an independent organization focused exclusively on diagnostic testing solutions. Alongside this transition, Siemens Healthineers has also announced plans to change its corporate name to Healthineers. Both organizational changes will take place in parallel as the company works toward establishing a new structure for its businesses and strengthening their respective market identities.
The introduction of Olyrian Diagnostics represents an important milestone for the diagnostics business, which has a history of more than a century in the healthcare industry. The new brand is intended to establish a distinct identity for the business as it prepares to operate independently. With a focus on in vitro diagnostics, laboratory testing and point-of-care solutions, Olyrian Diagnostics aims to support healthcare professionals with technologies and services that help deliver important diagnostic information. The company will continue to build on its existing capabilities while preparing for its next phase of development in the global diagnostics market.
The new brand has been introduced with the purpose of “Powering human potential at the heart of care.” This statement reflects the company’s commitment to placing people at the center of healthcare and recognizing the important role diagnostic information plays in clinical decision-making. Olyrian Diagnostics intends to connect intelligent technologies with the expertise of laboratory professionals, healthcare providers and other specialists who rely on accurate diagnostic results. Its approach will focus on supporting healthcare teams throughout the testing process, from collecting patient samples and conducting laboratory investigations to interpreting results and determining appropriate next steps in patient care.
Sharon Bracken, head of Diagnostics for Siemens Healthineers, highlighted the importance of combining technological capabilities with the knowledge and experience of healthcare professionals. She explained that technology creates opportunities, but people are responsible for turning those opportunities into improved patient care and better health outcomes. Every day, laboratory teams and healthcare professionals depend on diagnostic systems to provide critical information that supports patient treatment decisions. By developing connected workflows and intelligent diagnostic solutions, the business aims to improve efficiency and provide a more comprehensive understanding of individual patient health.
Bracken also emphasized that informed and connected workflows can help healthcare professionals work more efficiently while strengthening their ability to interpret diagnostic information. Whether a professional is conducting a laboratory test, reviewing results or deciding on the next stage of treatment, reliable diagnostic technologies remain essential throughout the healthcare journey. She described Olyrian Diagnostics as the beginning of a new chapter for the business, recognizing its established history while expressing confidence in its future opportunities. The new identity is intended to reflect the company’s commitment to supporting the people who make, interpret and act on diagnostic information.
Olyrian Diagnostics Prepares for Independent Operations
The decision to establish Olyrian Diagnostics as a separate brand represents the next stage in preparing Siemens Healthineers’ in vitro diagnostics business for standalone operations. The carve-out process is expected to be completed by mid-2028, creating a dedicated organization with its own market identity and strategic direction. The transition is designed to position the diagnostics business as one of the largest standalone companies focused specifically on the diagnostics industry. By establishing a distinct brand, the organization aims to strengthen its visibility among customers, healthcare providers, laboratory networks and other industry stakeholders.
The new company will focus on providing diagnostic solutions across different stages of healthcare delivery, ranging from patient sample collection to population health management. Its portfolio will include technologies designed for clinical laboratories as well as point-of-care testing environments. These solutions play an important role in helping healthcare professionals identify diseases, monitor medical conditions and support treatment decisions. By concentrating on in vitro diagnostics, Olyrian Diagnostics intends to strengthen its position in a market where accurate testing, operational efficiency and timely access to diagnostic information are increasingly important.
The company’s purpose, “Powering human potential at the heart of care,” will guide its future business direction and reinforce its focus on the people involved in healthcare delivery. Diagnostic technologies are essential to modern medicine because they provide information that helps healthcare professionals understand patient conditions and make informed clinical decisions. However, the value of these technologies also depends on the professionals who operate testing systems, evaluate laboratory findings and translate diagnostic results into appropriate care pathways. Olyrian Diagnostics aims to bring these capabilities together through a combination of intelligent technology, connected systems and professional expertise.
The standalone structure is expected to provide the diagnostics business with a more clearly defined identity within the global healthcare technology market. As a dedicated diagnostics-focused organization, Olyrian will be able to concentrate its strategic priorities on laboratory testing, point-of-care diagnostics, automation and related digital solutions. The transition also provides an opportunity to strengthen customer relationships and build on the company’s existing international presence. Its established portfolio and technical expertise will remain important foundations as the business prepares for its new organizational structure.
Customer Operations and Services to Continue During the Transition
Although the business is preparing to become a standalone organization, Olyrian Diagnostics will remain part of Siemens Healthineers throughout the carve-out transition. The company has emphasized that the introduction of the new name does not mean an immediate change in its existing customer relationships or operational arrangements. Customers can continue working with the same business teams and expect the established commitment to product quality, service delivery and innovation. This continuity is intended to ensure that healthcare organizations and laboratory customers can maintain their regular operations while the organizational separation progresses.
As of the announcement, there will be no immediate changes to existing products, services, customer contracts, service levels or points of contact. Healthcare providers and laboratory organizations will continue receiving support through their existing arrangements. The company has also indicated that customers will receive updates as the carve-out process develops. Any future changes affecting business operations, customer agreements or service arrangements will be communicated directly to the relevant stakeholders. This approach is intended to provide transparency and reduce uncertainty for customers during the transition period.
Maintaining operational stability will be particularly important because diagnostic testing services are closely connected to everyday healthcare delivery. Hospitals, clinical laboratories, diagnostic centers and healthcare networks depend on reliable testing equipment and consistent service support to manage patient workloads. Any disruption to laboratory systems or testing services could affect the availability of diagnostic information and the efficiency of healthcare operations. By maintaining existing customer arrangements during the transition, Olyrian Diagnostics aims to provide continuity while preparing for its future independent structure.
The company’s existing relationships with healthcare professionals and laboratory customers will also remain an important part of its business strategy. Diagnostic solutions are used across multiple healthcare environments, and customers often depend on long-term relationships with technology providers for equipment, maintenance, technical assistance and laboratory workflow management. Olyrian Diagnostics will build on these established connections as it develops its independent market presence. Its commitment to service quality and innovation is expected to remain central to its approach throughout the organizational transition.
More Than a Century of Diagnostic Innovation
Olyrian Diagnostics will build on the long-standing history of Siemens Healthineers’ in vitro diagnostics business, which has developed its capabilities through acquisitions and technological innovation. Siemens Healthineers established its current diagnostics business following the acquisition of three companies in 2006 and 2007. These organizations brought together established expertise and extensive experience in diagnostic testing, with histories dating back as far as 1884. Their combined capabilities helped create the foundation for a broad diagnostics portfolio serving healthcare organizations around the world.
Over the years, the business has contributed to several important developments in laboratory diagnostics. Its innovation history includes the introduction of the first urine test strip for diabetes and the industry’s first automated, integrated clinical chemistry and immunoassay analyzer. These developments represent important milestones in the evolution of diagnostic testing because they helped advance the availability and efficiency of laboratory-based medical investigations. The company’s technological progress has supported healthcare professionals in obtaining diagnostic information across a wide range of medical conditions.
Today, the diagnostics business manufactures more than 16 billion tests annually, supported by an assay portfolio covering nearly every major disease area. This extensive testing capacity reflects the scale of its operations and the importance of its solutions to healthcare systems. Diagnostic assays are used to detect and monitor a wide range of diseases and medical conditions, providing information that can support screening, diagnosis, treatment monitoring and ongoing patient management. The company’s broad portfolio enables it to serve different laboratory requirements and healthcare environments.
Its current product and service portfolio includes laboratory automation, diagnostic informatics and point-of-care testing solutions. Laboratory automation technologies are designed to improve testing workflows, reduce manual processes and support the efficient handling of large sample volumes. Diagnostic informatics solutions help laboratories manage information and connect testing activities with broader healthcare systems. Point-of-care testing technologies allow certain diagnostic investigations to be conducted closer to patients, potentially supporting faster access to test results in appropriate clinical settings.
These capabilities will form an important foundation for Olyrian Diagnostics as it prepares to operate independently. The company intends to build on its established expertise while continuing to develop technologies that support the changing requirements of healthcare providers. As diagnostic testing becomes increasingly important in modern healthcare, laboratory efficiency, reliable results and connected information systems are expected to remain significant areas of focus.
Strengthening the Role of Diagnostics in Modern Healthcare
The launch of Olyrian Diagnostics comes at a time when diagnostic testing continues to play an increasingly important role in healthcare delivery. Healthcare providers rely on laboratory and point-of-care testing to identify diseases, assess patient health and monitor responses to treatment. Accurate diagnostic information can help clinicians make informed decisions and determine appropriate care pathways. As healthcare systems manage growing patient populations and increasingly complex medical needs, the importance of reliable diagnostic technologies continues to expand.
Olyrian Diagnostics aims to address these requirements through a portfolio that combines testing technologies, automation and informatics capabilities. Its focus on connected workflows reflects the need for laboratories and healthcare professionals to access relevant diagnostic information efficiently. By supporting the people responsible for conducting tests and interpreting results, the business intends to contribute to more coordinated healthcare processes. The company’s purpose also recognizes that technology delivers its greatest value when it supports the expertise and decision-making of healthcare professionals.
The business will also continue to focus on both centralized laboratory environments and point-of-care testing. Large laboratories require systems that can manage significant testing volumes while maintaining operational efficiency and consistent quality. Meanwhile, point-of-care testing can provide diagnostic information in settings where timely results are particularly valuable. Serving these different environments gives the business an opportunity to support healthcare providers across multiple stages of patient care.
As Olyrian Diagnostics moves toward standalone operations, its established international presence, manufacturing capabilities and broad assay portfolio will provide a foundation for future development. The company will seek to maintain its history of innovation while aligning its business priorities with the evolving needs of healthcare customers. Its focus on people, technology and connected diagnostic workflows is expected to shape its identity in the global diagnostics industry.
A New Chapter for Siemens Healthineers and Olyrian Diagnostics
The parallel transitions involving Olyrian Diagnostics and Healthineers represent a significant organizational development for the companies. While the diagnostics business prepares to establish itself as a standalone organization, Siemens Healthineers will also move forward with its planned corporate name change to Healthineers. Both changes are intended to establish distinct identities and support the companies’ respective future directions.
For Olyrian Diagnostics, the immediate priority will be completing the carve-out process while maintaining business continuity for customers and healthcare partners. The expected completion timeline of mid-2028 provides a defined period for the organizational transition. During this time, the company will continue operating as part of Siemens Healthineers while preparing the structures and capabilities required for independent operations.
The new brand will carry forward more than a century of diagnostic expertise, a portfolio spanning major disease areas and manufacturing capacity exceeding 16 billion tests annually. It will also build on a history of innovation in diabetes testing, laboratory automation and integrated diagnostic technologies. By combining this established foundation with a dedicated focus on in vitro diagnostics, Olyrian Diagnostics aims to strengthen its position in the global healthcare market.
Ultimately, the introduction of Olyrian Diagnostics signals a new phase for the diagnostics business, with a clear emphasis on supporting healthcare professionals and improving the role of diagnostic information in patient care. Through intelligent technologies, laboratory expertise, point-of-care solutions and connected workflows, the company intends to continue advancing diagnostic capabilities. Its purpose of powering human potential at the heart of care will guide its next chapter as it prepares to become an independent diagnostics-focused organization by mid-2028.
Source link: https://www.siemens-healthineers.com/
